Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022160013 - SARS-COV-2 BINDING PROTEINS

Publication Number WO/2022/160013
Publication Date 04.08.2022
International Application No. PCT/AU2022/050044
International Filing Date 28.01.2022
IPC
A61K 39/395 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
C07K 16/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/46 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
G01N 33/563 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
563involving antibody fragments
G01N 33/569 2006.1
GPHYSICS
01MEASURING; TESTING
NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
33Investigating or analysing materials by specific methods not covered by groups G01N1/-G01N31/131
48Biological material, e.g. blood, urine; Haemocytometers
50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
53Immunoassay; Biospecific binding assay; Materials therefor
569for microorganisms, e.g. protozoa, bacteria, viruses
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
Applicants
  • THE WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH [AU]/[AU]
Inventors
  • THAM, Wei-Hong
  • ADAIR, Amy
  • PYMM, Phillip Gordon
Agents
  • FB RICE PTY LTD
Priority Data
202190018928.01.2021AU
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SARS-COV-2 BINDING PROTEINS
(FR) PROTÉINES DE LIAISON AU SRAS-COV-2
Abstract
(EN) The present invention relates generally to proteins, such as VHH nanobodies, which bind to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein in the receptor binding domain. The present invention also relates to methods of treating and diagnosing coronavirus disease 2019 (COVID-19).
(FR) La présente invention concerne de manière générale des protéines, telles que des nanocorps VHH, qui se lient à la protéine de spicule du coronavirus 2 du syndrome respiratoire aigu sévère (SRAS-CoV-2) dans le domaine de liaison au récepteur. La présente invention concerne également des procédés de traitement et de diagnostic d'une maladie de coronavirus 2019 (COVID-19).
Latest bibliographic data on file with the International Bureau